Australian researchers launch hydroxychloroquine trial in high-risk health workers

0 Comment(s)Print E-mail Xinhua, May 20, 2020
Adjust font size:

SYDNEY, May 20 (Xinhua) -- Thousands of frontline doctors and nurses in Australia will take part in a widespread clinical trial of hydroxychloroquine, a controversial drug that has been claimed to defend against COVID-19.

Announced on Wednesday and codenamed, the study COVID SHIELD will be led by Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, and funded by the Australian government.

Co-leader of the study, Professor Ian Wicks from the Royal Melbourne Hospital told Xinhua that hydroxychloroquine had been trialed before as a treatment for COVID-19, but the study was the first to test the drug as a preventive measure against the virus.

"As far as we are aware, it is the first double-blind, placebo-controlled trial to test for prevention," he told Xinhua. "We are hopeful this Australian trial will provide a definitive answer to this question."

During the four-month trial period, half of the 2,250 participants will be given hydroxychloroquine, while the other half will receive a placebo tablet.

Fellow co-leader of the study, Professor Marc Pellegrini from WEHI, described the multi-center, randomized, double-blind study, as "gold standard" in design.

"The trial is focused on our frontline and allied healthcare workers who are at an increased risk of infection due to repeated exposure caring for sick patients. Our aim is to help people stay safe, well and able to continue in their vital roles," Pellegrini said.

Earlier this week, the United States President Donald Trump revealed that he had been taking hydroxychloroquine himself for a number of weeks, despite inconclusive evidence to its effects and concerns for potential public misuse.

However, the drug has been widely prescribed by doctors in the past 50 years to treat diseases like malaria, lupus and rheumatoid arthritis, meaning that potential side effects are largely known and manageable within a clinical setting.

"Rheumatologists are very comfortable with the drug's safety profile. Like any medication, hydroxychloroquine has certain side effects, but fortunately, these are well known and quite uncommon," Wicks said.

"The medical specialists conducting COVID SHIELD are highly experienced in using hydroxychloroquine in the clinic. All participants will be screened based on rigorous selection criteria and closely monitored throughout the trial to ensure safety." Enditem

Follow on Twitter and Facebook to join the conversation.
ChinaNews App Download
Print E-mail Bookmark and Share

Go to Forum >>0 Comment(s)

No comments.

Add your comments...

  • User Name Required
  • Your Comment
  • Enter the words you see:   
    Racist, abusive and off-topic comments may be removed by the moderator.
Send your storiesGet more from